// App-Quantinova.ai

P2-02-21 : Longitudinal analysis of circulating tumor cells and cell free tumor DNA by next generation sequencing in triple negative breast cancer

Researchers

Presenter

  • Howard K

Principal Investigators

  • Ramirez AB

  • Tuuli S

  • Heying N

  • Deutsch K

  • Cox J

  • Lo FY

  • Stilwell JL

  • Kaldjian EP

  • Dorschner M

  • Blau S

  • Blau A

  • Ritter L

  • Eisenberg M

  • Boles D

  • Pruitt J

  • Collins H

  • Mahen E

  • Leonti A

  • Maassel L

  • Subia C

Medical Centers

  • Northwest Medical Specialties, PLLC, Puyallup, WA

  • Center for Cancer Innovation, University of Washington, Seattle, WA

  • Covance, Durham, NC

Locations

  • United States

Companies

  • RareCyte, Inc.

  • Laboratory Corporati

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Triple-negative breast cancer

  • Breast cancer

  • Solid malignancies

Biomarkers

  • Circulating tumor cells

  • Progesterone receptor

  • Human epidermal growth factor receptor 2

  • Plasma cell-free DNA

Drug/Treatment

  • Cisplatin

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved